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Abstract
Genetic interaction between donor and recipient may dictate the impending responses after transplantation. In this study,
we evaluated the role of the genetic predispositions of stromal-derived factor-1 (SDF1) [rs1801157 (G.A)] and CXC receptor
4 (CXCR4) [rs2228014 (C.T)] on renal allograft outcomes. A total of 335 pairs of recipients and donors were enrolled. Biopsy-
proven acute rejection (BPAR) and long-term graft survival were traced. Despite similar allele frequencies between donors
and recipients, minor allele of SDF1 rs1801157 (GA+AA) from donor, not from recipients, has a protective effect on the
development of BPAR compared to wild type donor (GG) (P=0.005). Adjustment for multiple covariates did not affect this
result (odds ratio 0.39, 95% C.I 0.20–0.76, P=0.006). CXCR4 rs2228014 polymorphisms from donor or recipient did not affect
the incidence of acute rejection. SDF1 was differentially expressed in renal tubular epithelium with acute rejection according
to genetic variations of donor rs1801157 showing higher expressions in the grafts from GG donors. Contrary to the
development of BPAR, the presence of minor allele rs1801157 A, especially homozygocity, predisposed poor graft survival
(P=0.001). This association was significant after adjusting for several risk factors (hazard ratio 3.01; 95% C.I=1.19–7.60;
P=0.020). The allelic variation of recipients, however, was not associated with graft loss. A donor-derived genetic
polymorphism of SDF1 has influenced the graft outcome. Thus, the genetic predisposition of donor should be carefully
considered in transplantation.
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Introduction
A variety of recently discovered potent immunosuppressive
agents have significantly improved short-term renal allograft
survival in the last two decades. However, long-term allograft
survival has not changed significantly. Although various
immunological and non-immunological factors may affect the
outcome of an allograft, the genetic interactions between donors
and recipients may also be an important aspect for the
impending responses after organ transplantation. Recently, we
demonstrated genetic interactions of the CCR5 cytokine be-
tween donors and recipients and its effects on allograft rejection
and allograft survival [1]. Although acute rejection (AR) and
subsequent chronic inflammatory processes are initiated by the
presentation of donor-antigens to recipient T cells, they are the
ultimate manifestations of active interactions between grafts and
recipients that mobilize various types of cells and humoral
factors.
Stromal-derived factor-1 (SDF1) is the ligand for chemokine
CXC receptor 4 (CXCR4). SDF1 is up-regulated in various
organs that respond to tissue damage from irradiation or hypoxia
[2]. SDF1 has a crucial role in stem cell mobilization, diffe-
rentiation, and homing and also is a highly potent chemoattractant
for monocytes and naive T cells [3,4]. Genetic polymorphism of
SDF1 has been reported to have an effect on the expression of
SDF1 [3,4] and affects patient survival in liver transplantation [5].
SDF1 expression is elevated in chronic renal allograft rejection [6].
However, the role of SDF1 expression controlled by genetic
polymorphisms has not been investigated thoroughly in the
transplantation field.
We assume that the graft outcome is dependent not only on the
recipient’s immune responses but also on the responses of the graft
as an active participant. Therefore, we hypothesized that genetic
variations in SDF1 and CXCR4 of donors as well as recipients
might alter leukocyte trafficking in the short-term and the tissue
repair process in the long-term, and would thereby be associated
with an increased risk of AR and long-term graft survival. To
evaluate this hypothesis, we analyzed the genetic variations of
SDF1 and CXCR4 with regard to donor-recipient genetic
interactions in kidney transplantation.
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Baseline characteristics and Genetic variations of SDF1-
CXCR4
All variables except for the recipient’s gender were not
significantly different between the BPAR (+) and BPAR (2)
groups (Table 1). Allele frequencies were deduced from the
genotype distribution. Minor allele frequencies of SDF1 polymor-
phisms [rs1801157 (G.A)] and CXCR4 polymorphism
[rs2228014 (C.T)] were 0.264, 0.113 in recipients, respectively,
and 0.249, 0.099 in donors. There was no significant difference in
allele frequencies between recipients and donors. Observed allele
frequencies did not differ significantly from expected allele
frequencies based on conformity with the Hardy-Weinberg
equilibrium.
Genetic variations and the development of acute
rejection
Among 335 recipients, 61 recipients (18.2%) experienced BPAR
after renal transplantation. Table 2 presents the results of analyses
for the association between genotypes of the SDF1 and CXCR4
polymorphism and risk for BPAR. Minor allele of SDF1
rs1801157 (GA+AA) from donor, not from recipients, has a
protective effect on the development of BPAR compared to wild
type donor (GG) [odds ratio (OR) 0.39, 95% confidence interval
(CI) 0.21–0.76, P=0.005] (Table 2). In the additive model of
genotype analysis, the odds ratio of BPAR per copy of donor
variant allele (A) was 0.43, which was significant (95% CI 0.24–
0.75, P for trend =0.003). Adjustment for multiple covariates did
not significantly affect this result (model 3, OR 0.39, 95% CI 0.20–
0.76, P=0.006] (Table 3). Allelic variation of recipients, however,
was not significantly associated with the occurrence of BPAR.
CXCR4 rs2228014 polymorphisms from donor or recipient did
not affect the incidence of acute rejection. (Table 2, 3) When we
examined 57 acute cellular rejection pathologic findings according
to donor SDF1 rs1801157 genetic variations (GG, n=43; GA,
n=13; AA, n=1), there were no significant differences between
the polymorphism and severity of acute rejection (Table S1).
Table 1. Baseline characteristics by incident biopsy-proven
acute rejection.
Total BPAR (2) BPAR (+)
P
value
n 335 274 61
Recipients’
gender (% male)
66.3 63.9 77.0 0.049
Recipients’ age (years) 36.5614.5 35.9614.5 39.4614.6 0.083
Donors’
gender (% male)
51.9 50.7 49.3 0.347
Donors’ age (years) 38.1611.5 38.1611.4 38.2612.3 0.978
No. of HLA mismatch 2.761.5 2.661.6 2.961.4 0.198
Hypertension (%) 0.803
No 35.5 35.4 36.1
ex-hypertension 24.5 25.2 21.3
Current hypertension 40.0 39.4 42.6
Diabetes mellitus (%) 0.661
No 86.6 87.2 83.6
PTDM 72. 6.6 9.8
original DM 6.3 6.2 6.6
No. of transplantation (%) 0.894
1
st 96.4 96.3 96.7
2
nd 3.3 3.3 3.3
3
rd 0.3 0.4 0
Donor type (%) 0.817
Living related 69.0 69.7 65.6
Living unrelated 20.9 20.4 23.0
Deceased 10.1 9.9 2.1
Data are presented as mean 6 standard deviation or proportion.
The t-test was used for continuous variables and the chi-square test was used
for categorical variables. BPAR, biopsy-proven acute rejection; PTDM,
posttransplant diabetes mellitus; DM, diabetes mellitus.
doi:10.1371/journal.pone.0016710.t001
Table 2. Genetic distribution of recipient/donor SDF1 and CXCR4 Single Nucleotide Polymorphisms.
Donor
P value
for trend Recipient
P value
for trend
Genotype
BPAR
(2), n (%)
BPAR
(+), n (%) OR (95% CI)
BPAR
(2), n (%)
BPAR
(+), n (%) OR (95% CI)
SDF-1 rs1801157 GG 138 (54.8) 43 (75.4) 1.00 (reference) 0.003 144 (53.7) 33 (55.9) 1.00 (reference) 0.460
GA 89 (35.3) 13 (22.8) 0.47 (0.24–0.92) 103 (38.4) 24 (40.7) 1.02 (0.57–1.82)
AA 25 (9.9) 1 (1.8) 0.13 (0.02–0.98) 21 (7.8) 2 (3.4) 0.42 (0.09–1.86)
GA+AA vs. GG 114 (45.2) 14 (24.6) 0.39 (0.21–0.76) 0.005 124 (46.3) 26 (44.1) 0.92 (0.52–1.61) 0.759
Total 252 (100) 57(100) 268(100) 59 (100)
CXCR4 rs2228014 CC 201 (58.0) 45 (80.4) 1.00 (reference) 0.975 201 (78.8) 45 (81.8) 1.00 (reference) 0.463
CT 43 (32.4) 11 (19.6) 1.14 (0.55–2.39) 49 (19.2) 10 (18.2) 0.91(0.43–1.94)
TT 3 (9.6) 0 (0.0) NA 5 (2.0) 0 (0.0) NA
CT+TT vs. CC 46 (42.0) 11 (19.6) 1.07 (0.51–2.22) 0.860 54 (21.2) 10 (18.2) 0.83 (0.39–1.75) 0.619
Total 247 (100) 56 (100) 255 (100) 55(100)
BPAR, biopsy-proven acute rejection; OR, odds ratio; CI, confidence interval; N/A, modeling not completed because SNP frequency =0% in BPAR (2) and/or BPAR (+).
doi:10.1371/journal.pone.0016710.t002
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polymorphism
The most prominent staining of SDF1 was detected in tubular
epithelium. When we compared the expression of SDF1 according
to donor SDF1 genotypes in 21 recipients who experienced BPAR,
we found that SDF1 expression was significantly higher in the graft
from donors with the wild-type genotype (GG) compared with the
GA or AA genotype (mean staining score 6 SE, 3.160.3 vs.
1.960.3, P=0.028, Figure 1B). Recipients’ polymorphisms did
not affect SDF1 expression (data not shown).
Long-term graft survival and SDF1 rs1801157
polymorphism
When we performed a survival analysis using the Kaplan-Meier
method, recipients receiving the homozygous variant allele (AA)
from donors showed poor graft survival compared to recipients
who received kidneys with the wild-type (GG) or heterozygous
genotype (GA) in the log-rank test, contrary to the association of
BPAR and SDF1 polymorphism (Figure 2B and 2C, P=0.005,
0.001, respectively). The median graft survival of recipients who
had grafts from AA donors was significantly shorter than those of
grafts from GG or GA donors (9.8 vs. 17.2 years). Again, recipients’
polymorphisms did not affect graft survival.
Next, we performed a subgroup analysis according to the
presence of BPAR. In recipients who had not experienced BPAR,
subjects with AA grafts had significantly poorer allograft survival
(Figure 3A, P,0.001). In recipients experiencing BPAR, the
number of recipients with AA grafts was too small. No one had lost
an AA graft (Figure 3B, P value=0.932).
Univariate and multivariate Cox regression analyses were
performed after adjusting for several factors including BPAR.
Unadjusted Cox regression analysis revealed that individuals
carrying the AA genotype had an increased hazard ratio of graft
loss (AA versus GG + GA genotype, hazard ratio =3.63, 95% CI
1.57–8.39, P=0.003). This association was statistically significant
after adjusting for several risk factors (Model 5, hazard ratio
=3.01; 95% CI 1.19–7.60, P value =0.020) (Table 4).
Discussion
Our analysis identified a statistically significant association
between the rs1801157 genetic variation at 3’ UTR of SDF1 and
graft outcome in terms of BPAR and graft loss after kidney
transplantation. Specifically, the presence of the rs1801157
polymorphism variant allele of donors was associated with a
significantly lower risk of BPAR, but it increased the risk of graft
loss irrespective of BPAR.
Kidney tubular epithelial cells express cytokines, chemokines, or
many of their receptors. They may play different roles in allograft
rejection and chronic allograft dysfunction. Therefore, polymor-
phisms of cytokine and chemokine gene expression have been
recognized as significant variables affecting allograft outcome.
Recently, we reported that a CCR5 polymorphism in donors and
recipients contribute together to provoke subsequent acute
rejection in the early period and influence graft outcome in the
later phase [1]. CXCR4 is the receptor of SDF1 and is expressed
on several cells such as hemato/lymphopoietic cells, stem/
progenitor cells, and several tumor cells [2]. SDF1 is up-regulated
after ischemic injury to various organs [7–10] and leads to
improved vasculogenesis and neovascularization through the
recruitment of bone marrow-derived circulating endothelial
progenitor cells to ischemic regions [11]. Besides these effects, it
plays a crucial role in the retention of inflammatory cells [12].
Therefore, the SDF1/CXCR4 axis may be considered to be a
potential target for therapeutic modifications. The SDF1/CXCR4
axis was suggested as an important regulator of allograft rejection
and graft/patient survival. In liver recipients with acute and
chronic allograft rejection, CXCR4+ T lymphocytes infiltrated
SDF1 expressing bile ducts [13]. The SDF1 rs1801157 minor
allele (A) of liver recipients was a significant risk factor for patient’s
survival, but did not affect rejection or graft survival [5]. In human
heart transplantation, SDF1 was elevated and was involved in
recruiting stem cells [14]. SDF1 positive cells infiltrate significantly
more into the interstitium and arteries in chronic allograft
nephropathy [8]. The SDF1 rs1801157 polymorphism came into
the spotlight because the homozygous AA polymorphism delayed
the onset of AIDS and prolonged survival of individuals infected
with HIV-1 [15]. Afterward, this polymorphism has been
investigated in many fields of study such as cancer and
atherosclerosis [16–20]. CXCR7 has been found as a new
receptor for SDF1. CXCR7 was expressed on both stem cells
and inflammatory cells like CXCR4, although there has been
some controversy until now [21]. Matthias AN et al. recently
reported the role of chemokine receptor CXCR7 in renal allograft
Table 3. The independent risk factor to the incidence of acute rejection analyzed by multivariate logistic regression.
Donor Recipient
OR 95% CI P value OR 95% CI P value
SDF-1 rs1801157 GA+AA vs. GG GA+AA vs. GG
Model 1
a 0.40 0.21–0.78 0.007 0.88 0.50–1.57 0.666
Model 2
b 0.40 0.21–0.77 0.006 0.88 0.50–1.57 0.674
Model 3
c 0.39 0.20–0.76 0.006 0.88 0.49–1.57 0.657
CXCR4 rs2228014 CT+TT vs. CC CT+TT vs. CC
Model 1
a 1.12 0.53–2.34 0.772 0.90 0.42–1.93 0.793
Model 2
b 1.11 0.53–2.34 0.778 0.92 0.43–1.98 0.831
Model 3
c 1.11 0.53–2.34 0.785 0.92 0.43–1.97 0.819
a, adjusted for recipient’s age and recipient’s gender;
b, adjusted for recipient’s age, recipient’s gender, number of HLA mismatching, donor type;
c, adjusted for recipient’s age, recipient’s gender, number of HLA mismatching, donor type, number of transplantation, hypertension, and diabetes mellitus.
OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0016710.t003
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was significantly increased in acute allograft rejection. This finding
is parallel with our present study.
This study showed that the presence of the rs1801157 variant
allele (A) was associated with a significantly lower risk of BPAR,
but it increased the risk of graft loss. It is unusual that one cytokine
or chemokine performs in a different way in acute rejection than in
chronic allograft nephropathy. In accordance with our results,
IFN-c prevented necrosis during a rejection process, but it
potentiated chronic allograft dysfunction [23]. Yet, the role of
SDF1 rs1801157 in 39 UTR has not been well investigated in
kidney transplantation. Although the SDF1 rs1801157 minor
allele isoform (AA or GA) may significantly decrease plasma SDF1
level compared to the wild-type isoform (GG) [3], the relationship
between the rs1801157 polymorphism and plasma SDF1 level or
stem cell number is still controversial [4]. Although donor SDF1
polymorphisms could not alter plasma level after operation,
intragraft SDF1 expression might be influenced [24], consequently
leading to a change in cellular recruitment. If the rs1801157 minor
allele (A) polymorphism decreased intragraft SDF1 expression,
there would be less inflammation in the early period, and a
decrease in acute rejection. At the later phase, however, it would
reduce tissue repair and make chronic allograft nephropathy more
severe. Although the number of biopsies performed with
Figure 1. Semi-quantitative evaluation of the expression of SDF-1 in the kidney tubular epithelium proven acute cellular rejection.
(A) Score 1, no staining or faint staining in a few tubules; score 2, weak staining; score 3, moderate staining; score 4, strong staining. (B) SDF-1
intensity scores according to donors’ genetic variation of SDF-1 rs1801157, P value, Mann Whitney test.
doi:10.1371/journal.pone.0016710.g001
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was small, the pattern in acute rejection is in agreement with the
above-mentioned hypothesis.
Our results are informative, but this study has some limitations.
First, the number of recipients transplanted from AA donor, who
had a significant low graft survival, was small. There may be a
likelihood of type 1 error. Study dealing with more large number
of population is necessary to confirm our finding that polymor-
phism of SDF1 affect graft survival. Second, the protocol biopsy
and works for the functional relationship of the SDF1 rs1801157
sequence variation of donor with BPAR or renal graft loss will be
necessary.
In conclusion, a donor-derived, not recipient-derived, genetic
SDF1 polymorphism has different effects on graft outcome. Thus,
the genetic influence from donors should be carefully considered
for the proper management of allografts after kidney transplan-
tation.
Materials and Methods
Patients
A total of 335 pairs of Korean recipients and donors who were
followed-up for at least 1 year were recruited for this study. They
had received kidney transplants at Seoul National University
Hospital between 1982 and 2008. We collected whole blood
samples from the patients and their donors as follows: 307 samples
from donors and recipients; 22 from recipients only; 6 from a
donor only. The research protocol used for this study was
approved by the Internal Review Board of Seoul National
University Hospital (IRB No.H-0911-011-299). Written informed
consents have been obtained and all clinical investigations have
been conducted according to the principles expressed in the
Declaration of Helsinki. We conducted medical record reviews of
recipients based on the electronic medical record system. Clinical
parameters that could have influenced graft outcome were
collected, i.e. recipient’s gender and age at transplantation, history
of hypertension, diabetes mellitus, and donor type. The primary
outcome of this study was biopsy-proven acute rejection (BPAR)
within 1 year of the transplant. The secondary outcome was graft
loss which was defined as graft dysfunction that necessitated new
renal replacement therapy after transplantation.
Genotyping
DNA was extracted from whole blood, and genotyping for
SDF1 [rs1801157 (G.A)] and CXCR4 [rs2228014 (C.T)] was
carried out by the TaqManH method (Applied Biosystems,
7900HT Fast real time PCR system, USA). Primers used for
SDF1 and CXCR4 were as follows: SDF1 rs1801157 59-
GTGAAGGCTTCTCTCTGTGGGA-39 and 59-TCTGCCC-
TGGCCTCACAC-39; CXCR4 rs2228014 59-CAACCTCTA-
CAGCAGTGTCCTCAT-39 and 59-CAGCTTCCTTGGCCT-
CTGAC-39.
A different fluorescence label [6-carboxyfluorescein (FAM) for
mutant and 6-carboxy-4,7,29,79-tetrachlorofluorescein (TET) for
wild type] was used to label the 59 segment of allelic probes. Probe
sequences as follows: SDF1 rs1801157 59 (FAM)-CATGGGA-
GCCGGGTCTGCC-39 (TAMRA) and 59 (TET)-CATGGGA-
GCCAGGTCTGCCTCTT-39 (TAMRA); CXCR4 rs2228014 59
(FAM)-CGCTACCTGGCCATCGTCCA-39 (TAMRA) and 59
(TET)-CTGGCCATTGTCCACGCCAC-39 (TAMRA). Reaction
Figure 2. Graft survival according to SDF-1 rs1801157 (G.A)
genotypes. (A) Recipients, and (B, C) donors. P value, log-rank test.
doi:10.1371/journal.pone.0016710.g002
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deoxynucleotide triphosphates (2.5 mM each), 0.2 mL forward
primer (20 pmol/mL), 0.2 mL reverse primer (20 pmol/mL),
1.0 mL genomic DNA (50 ng/mL) and 0.15 mLi M a xI IT a q
polymerase. PCR reactions were carried out under the following
conditions:5 min94uC(one cycle);30 s94uC;30 s56uC(35cycles);
50 s 72uC, 7 min 72uC (one cycle). PCR products were analysed on
2% agarose gels. Confirmation of genotypes was done by repeated
PCR and DNA sequencing using the ABI Prism BigDye
Terminator Kit (Applied Biosystems, Foster City, CA, USA) of
10% of the study population samples.
Tissue immunohistochemistry staining and analysis
For the immunohistochemistry study, paraffin embedded
graft blocks of recipients diagnosed as BPAR were collected and
cut into 4 mm slices. Xylene and ethanol were used for
deparaffinization and hydration. Endogenous streptavidin
activity was blocked by 3% hydrogen peroxide (H2O2). To
examine the expression of human SDF1, deparaffinized sections
were stained with 1:200 diluted anti-SDF1 antibody (R&D
Systems, Minneapolis, MN) and incubated at 4uCo v e r n i g h t .
Sections were then incubated with biotin-conjugated anti-mouse
IgG biotinylated secondary antibody (Dako, Carpinterı ´a, CA).
Streptavidin and 3, 39-diaminobenzidine tetrahydrochloride
(Sigma–Aldridge, St. Louis, MO) were used for immunohisto-
chemical detection. Sections were then counterstained with
Mayer’s hematoxylin and examined by light microscopy. The
SDF1 score was graded in a blinded fashion by a renal
pathologist. The score was expressed semi-quantitatively as 1
to 4 as follows. Score 1 indicated basically no staining or faint
staining in a few tubules, score 2 indicated weak staining, score 3
corresponded to moderate staining, and score 4 signified strong
staining (Figure 1A).
Statistical analysis
We used SPSS for Windows package 12.0K (SPSS Inc.,
Chicago, IL) for all analyses and calculations. Student’s t-test
was used for continuous variables, and they were presented as
mean 6 SD. The chi-square test wasu s e df o rc a t e g o r i c a l
variables. Graft survival was analysed using the Kaplan–Meier
method, and comparison among groups was performed by the
log-rank test. We performed multivariate analysis using a binary
logistic regression test for risk of BPAR and the Cox regression
test for risk of graft loss, respectively (backward stepwise
method). Values of P,0.05 were considered as statistically
significant.
Table 4. Graft loss risk of recipients with donor SDF1
rs1801157 AA versus GG+GA by Cox regression analysis.
Hazard ratio 95% confidence interval P value
Model 1
a 3.63 1.57–8.39 0.003
Model 2
b 3.24 1.38–7.59 0.007
Model 3
c 2.75 1.17–6.48 0.021
Model 4
d 3.92 1.57–9.79 0.003
Modle 5
e 3.01 1.19–7.60 0.020
a, unadjusted;
b, adjusted for recipient’s age and gender;
c, adjusted for recipient’s age, gender, number of HLA mismatching, donor
type;
d, adjusted for recipient’s age, gender, number of HLA mismatching, donor
type, and biopsy-proven acute rejection.
e, adjusted for recipient’s age, gender, number of HLA mismatching, donor
type, biopsy-proven acute rejection, number of transplantation, diabetes
mellitus and hypertension.
doi:10.1371/journal.pone.0016710.t004
Figure 3. Graft survival according to donors’ genetic variation
of SDF-1 rs1801157 (G.A). (A) The biopsy-proven acute rejection
(2) group, and (B) the biopsy-proven acute rejection (+) group. P value,
log-rank test.
doi:10.1371/journal.pone.0016710.g003
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